2024 Replays

Dassault Systèmes' Science Week 2024 started with "Science in the Age of Experience - Generative Sciences for Society", gathering worldwide Scientific Communities to leverage the power of virtual universes and platforms.

As Patrick Johnson, Executive Vice President of Corporate Research and Sciences at Dassault Systèmes, explains in his welcoming remark, virtual worlds aim to expand knowledge and enable sustainable innovation. They open up all possibilities and take advantage of Generative science to elevate practices, knowledge, and potential. These universes become accessible to everyone, offering learning capacity at scale for our societies.

Science and innovation are part of our DNA. Our virtual universes are the testing ground for those who are working to address the great challenges facing humanity today. 3D design, digital mock-up (DMU), product life cycle management (PLM): we are certainly where you expect us to be, but our impact extends well beyond!

This conference is granted the official Paris AI Summit label

During "Science in the Age of Experience 2024 - Generative Sciences for Society", part 1 of Dassault Systèmes' Science Week 2024, Bernard Charlès, Executive Chairman of Dassault Systèmes, discussed in detail our vision of science and the virtualization of the world around 3 main ideas:

1. The role of science in creating, exploring and inhabiting "new worlds"
2. Virtual twins are environments for science
3. What it means to do "V+R science"

​​​​​​​Enjoy the Science in the Age Conference!

This conference is granted the official Paris AI Summit label

​​​​​​​"Science in the Age of Experience 2024 - Generative Sciences for Society" also discussed the world of industry facing multiple challenges, from the race for sustainability, supply chain disruptions and new policies, new technologies and complexities, and the value generated by use in this new experience economy.

Cédric Merlin, Group Director of AI4ALL for Valeo introduced us to the power of virtual twins and how they are revolutionizing innovation in industries, and examined the impact of AI on the world of mobility.

Valeo is taking on new technological challenges to differentiate itself in the market and accelerate its innovation.
• They are creating a virtual ecosystem with generative design and data science capabilities in several areas of R&D, procurement, manufacturing and others.
• The goal is to make the car more electrified, autonomous and software-driven, more connected.
• And of course Valeo is deploying Dassault Systèmes' 3DEXPERIENCE platform with CATIA Magic to optimize the development of new technologies for safer and more sustainable mobility

This conference is granted the official Paris AI Summit label

​​​​​​​In this "Science in the Age of Experience 2024 - Generative Sciences for Society" conference, Professor Georges Karniadakis from Brow University reviews physics-informed neural networks (NNs) and summarize available extensions for applications in computational science and engineering. He also introduced new NNs that learn functionals and nonlinear operators from functions and corresponding responses for system identification.

These two key developments have formed the backbone of scientific machine learning that has disrupted the path of computational science and engineering and has created new opportunities for all scientific domains. We will discuss some of these opportunities in digital twins, autonomy, materials discovery, etc.

This conference is granted the official Paris AI Summit label

Luis Sentis, Professor in Aerospace Engineering and Engineering Mechanics at the University of Texas at Austin, founder of the robotics company Apptronik Systems is actively engaged in research aimed at laying the groundwork for understanding the role of robots in communities.

During "Science In The Age Of Experience 2024 - Generative Sciences for Society", Luis Sentis told us that while the price of humanoid robots decreased to a historical minimum, the industrial sector feverishly debates about their productivity. What will be the killer App of humanoids be and where we will likely see them popping up? This talk will delve into such market dynamics and technical questions regarding the symbiosis of the physical mechatronic embodiments of humanoids, new interfaces to teach them at scale, and their deployment in larger setups industrial setups.

New approaches to managing complexity, uncertainty and chaos in times of crisis. This is a critical issue at a time of escalating conflicts, increasing climatic crisis, food crisis, supply chain disruptions that are features of our BANI World ('brittle', 'anxious', 'nonlinear' and 'incomprehensible'.) At "Science In The Age Of Experience 2024 - Generative Sciences for Society", we were lucky to have with us a prolific thinker, writer and risk assessor of complexity.

Dave Snowden is the Director of the Cynefin Centre for Applied Complexity. He co-led a major US Government project on counter-terrorism before and after 911. As a result, he was one of the principal designers of the Singapore Government’s Risk Assessment and Horizon Scanning system. Mr Snowden will discuss how project management can be inspired by nature and evolve as a domain with adaptive complex system thinking.

After working for ten years at Pfizer as a computational chemist specializing in chemoinformatics, Willem van Hoorn joined an AI-powered drug discovery company. Now an independent consultant, he joined "Science In The Age Of Experience 2024 - Generative Sciences for Society" to share his insights on how AI can accelerate drug discovery, why it hasn’t been as fast as we hoped, and what it takes to get back on track:

​​​​​​​The first wave of companies that pioneered the use AI in drug discovery were founded around 2010, claiming to dramatically speed up the rate of drug discovery. More than a decade has now passed, so where are the promised drug candidates?

A quick glance on your favourite social network feed will include multiple headlines decrying the failure of AI in drug discovery. I was cofounder of one of these companies and spent more than a decade there. Was it all hype and were my efforts in vain or is this a case of unrealistic expectations that were never going to be fulfilled? I argue the latter, reports of the death of AI in drug discovery are greatly exaggerated.

Gabe Gomes became a member of Carnegie Mellon University in 2022, affiliating with the Departments of Chemistry and Chemical Engineering. The Gomes Group's research centers on advancing chemical reactions, catalysts, and materials through cutting-edge machine learning and automated synthesis techniques. Positioned at the intersection of machine learning and organic chemistry, Gomes' work focuses on creating innovative platforms for autonomous reaction discovery, with a particular emphasis on catalysis.

This conference is granted the official Paris AI Summit label

This roundtable of "Science in the Age of Experience 2024 - Generative Sciences for Society" moderated by Claire Biot, VP Life Sciences and Healthcare at Dassult Systèmes, comprises inspiring leaders from the medical indutry. They shared a regulatory perspective on the challenges and many opportunities associated with reusing and sharing historical clinical trials or real-world data. Particular attention was paid to data sharing to create synthetic controls in clinical product development.

While prospective randomized controlled trials are the gold standard for most late phase medical product development, there are certain settings where assigning patients to the current standard of care represents significant patient burden. In some cases, clinical equipoise may be questioned. There are resulting challenges in recruitment, retention, or compliance which can compromise study completion and ability to address the research question.

We were lucky to have with us:

• Sammi Tang, PhD, MBA, Vice President of Global Biometrics Department at Servier, a pharmaceutical group dedicated to tackling health challenges in particular cancer and cardiovascular diseases.
• Ruthie Davi, PhD, Senior Vice President, Statistics and Regulatory Science Innovation, Medidata Solutions, the leading provider of SaaS and data analytics solutions that support clinical research.
• Benjamin Besse, MD, PhD, Director of Clinical Research at Institut Gustave Roussy. The first cancer research and treatment center in France and Europe, maintains its position in the top 5 hospitals for oncology globally. As an internationally renowned Institute, Gustave Roussy is treating adults and children suffering frequent or rare cancers, at all stages of the disease.
• Shaun Rowark, MS, Associate Director - Data Access and Analysis, National Institute for Health and Care Excellence (NICE). NICE provides national guidance and advice to improve health and social care in the UK. NICE is an executive non-departmental public body, sponsored by the Department of Health and Social Care. Its recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
  
  This conference is granted the official Paris AI Summit label

David Sourdive is a co-founder Executive Vice President, CMC & Manufacturing at Cellectis, a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer. During "Science in the Age of Experience 2024 - Generative Siences for Society", he shared his insights on how the next Generation CAR T-cells will contribute to curing cancer:

Cells are sophisticated objects capable of interacting with and reacting to their environment in powerful ways. As the first gene editing company ever founded, Cellectis has been at the forefront of two revolutions that make cells transition from the realm of individual grafts to that of mass-produced industrial drugs and deliver their full promise as they enter our pharmaceutical arsenal.

Overcoming the donor/recipient compatibility barrier to make off-the-shelf cell-based cancer drugs was the first revolution, initiated when inventing allogeneic CAR-T products and developing robust, scalable industrial manufacturing for these potent cell-based anti-cancer drugs.

Yet genome engineering goes beyond, enabling advanced genomic circuitry and programming cells to execute chosen therapeutic scenarios in patients to treat complex diseases. This second revolution marks a new era: the age of smart cells, intelligent cellular constructs that can be likened to living drones within the body, capable of autonomously navigating and targeting diseases with precision.

Cells are transforming into a field of innovation for engineers, promising more effective and less invasive treatment options for patients worldwide, and revolutionizing the treatment of cancer and other complex diseases.

Sarah Reisinger, Chief Science & Research Officer for dsm-firmenich, a global leader in health, nutrition, and beauty. Sarah combines an extensive background in biotechnology with a strong track record in ingredients and technology development for the consumer goods industry.

At “Science in the Age of Experience 2024 – Generative Science for Society,” Sarah detailed the cutting-edge advances her company has made in sustainability, improving the customer experience, making it more desirable and environmentally friendly, and catalyzing a regenerative economy:

We all know that our smartphones, computers, and cameras are jam-packed with scientific innovations. But many of us are less aware of the cutting-edge science that goes into our shampoos, our laundry detergents, our perfumes, and other daily household products. To maximize both performance and sustainability, these products harness green chemistry, materials science, bioinspiration, and more. Plus, modern neuroscience is lifting the lid on the enormous power the scents in these products can play in improving our focus and sense of wellbeing.

Even small innovations can add up to make big differences. Because science is everywhere, science has the power to have an enormous impact on our lives: it can be used to dramatically enhance our daily experiences, to help each of us perform to our maximum potential, and to ensure a healthy and sustainable planet.

Jean-Luc Alexandre is is the CEO of NAAREA (Nuclear Abundant Affordable Resourceful Energy for All), a French company proposing an alternative to fossil fuels, thanks to innovative and sustainable next-generation nuclear power. For “Science in the Age of Experience 2024 - Generative Sciences for Society”, Jean-Luc presented how NAAREA will produce carbon-free energy by reusing long-lived nuclear waste, developing advanced extra-small modular reactors that can be industrially mass-produced and installed close to consumers:

Our planet is overheating. The Intergovernmental Panel on Climate Change’s May 2023 report predicts that global warming is likely to result in a 1.5°C increase in the world’s average surface temperature by early 2030, and that maintaining this already excessive level would mean achieving net-zero global greenhouse gas emissions. In other words, the climate emergency is real: if we don’t find a way to radically change course, our planet will soon become uninhabitable.

The energy transition is an absolute necessity. Some people think we have to choose between economic growth and the environment. On the contrary, these two imperatives can be reconciled with energy that is sustainable, clean, abundant, safe and affordable.

With this aim, NAAREA (Nuclear Abundant Affordable Resourceful Energy for All) is developing the XAMR® (eXtrasmall Advanced Modular Reactor), a molten salt fast neutron microreactor capable of producing electricity (40 megawatts electric) and heat (80 megawatts thermal) that will burn plutonium and the most highly radiotoxic waste (with a lifetime of over 100,000 years) produced by nuclear power plants. The XAMR® is designed to be industrially mass-produced and installed in close proximity to consumers, namely in the mobility sector, electro-intensive industries and remote areas.

Dr. Gurtej S Sandhu, Principal Fellow and Vice President, Technology Development, Micron Technology, Inc. - whose industry-leading technologies enable the latest generation of faster, more intelligent global infrastructures that make AI model training, machine learning training and generative AI solutions possible - allowed the audience of "Science in the Age of Experience 2024 - Generative Sciences for Society" to take an interest in the world of new memory chip technologies and the unprecedented demand for new materials research and innovation:

Without advances in how the world physically stores and retrieves data, today’s most useful computer devices and algorithms would not exist. The dominant memory chip technologies rode the wave of innovations in materials, process and device technologies to scale down the path of Moore’s law. Although physical scaling is becoming increasingly difficult, the forces and market pull driving cost, power and density scaling are growing relentlessly. A commitment to innovation and creativity is needed to help fuel the next generation of technologies such as self-driving cars, space exploration and artificial intelligence (AI), which sounded like science fiction not so long ago.

Over the last decades, several flavors of new memory technologies based on alternate state variables have been under development. This is driving unprecedented demand for new materials research and innovation. One of them based on DNA (Deoxyribo-Nucleic acid) materials has a retention time far exceeding electronic memory. As an alternative storage media, DNA surpasses the information density and energy of operation offered by existing memory technologies. There are however several barriers and challenges to harness this potential of DNA to realize a fully functional storage system able to deliver performance and cost for a practical solution.

So many incredible initiatives are happening across the world and here again looking at DNA in new ways

SPYGEN heads up many of these amazing initiatives. It is a service and research laboratory specialised in the monitoring of aquatic and terrestrial biodiversity using environmental DNA (eDNA).

For “Science in the Age of Experience 2024 - Generative Sciences for Society”, we were fortunate to welcome Vincent Prié, one of SPYGEN’s senior project leaders to eplain how their cutting edge technology takes the study of all life from bacteria to large mammals to new heights.

As pointed out by Einstein, and confirmed by the violation of Bell’s inequalities, entanglement of separated particles is an extraordinary feature of quantum mechanics, suggesting some kind of non-locality. It is now used in quantum technologies.

After recalling what are Bell’s inequalities and their experimental tests, I will show how the notion of non-locality provides fruitful intuitions for some quantum communication methods.

Alain Aspect is an alumnus of ENSET Cachan (now ENS Paris-Saclay) and Orsay University. He is currently Professor at the Institut d'Optique-Université Paris-Saclay and Professor at the École Polytechnique. His doctoral thesis (1983), at the Institut d'Optique, focused on experimental tests of the foundations of quantum mechanics (tests of Bell's inequalities, for which he was awarded the 2022 Nobel Prize in Physics along with John Clauser and Anton Zeilinger). After experiments on single photons, with Philippe Grangier (1984-86), he worked on laser cooling of atoms at the Kastler Brossel laboratory of ENS Paris, with Claude Cohen-Tannoudji, Jean Dalibard and Christophe Salomon. The group he founded at the Institut d'Optique in 1993 focuses on atomic quantum optics and atomic quantum simulators with degenerate gases.
​​​​​​​
Alain Aspect is a member of the Académie des Sciences, the Académie des Technologies and several foreign academies (Austria, Belgium, Italy, UK, USA).

Contemporary transitions call for strong innovation and creation: new mobility, new energy, new industrial products and processes, etc. But contemporary transitions also call for strong preservation : preserve natural resources, existing infrastructures, way of living. Hence contemporary transition call for a non Schumpeterian type of innovation : creative preservation. ‘Creative preservation’ might sound like a paradox or a logical aporia. However recent advances in generativity science show that design theory combined with advanced knowledge models (C-K theory + topos theory) account for rigorous, logical models of creative preservation.

In this presentation we provide some elements to answer to the following questions: why contemporary transitions require creative preservation? How do generativity science formally account for creative preservation? How do creative preservation unfold in practice to design for transitions?

Pascal Le Masson is Professor at Mines Paris– PSL Research University, Chair of Bauhaus for Transitions. He is a member of the National Academy of Technology of France. With his colleagues of the Bauhaus for Transitions, a research and education chair supported by more than twenty partners actors of transition, they work on generative processes, design-oriented management and the design for transitions.
​​​​​​​
He co-chairs (with Eswaran Subrahmanian, Carnegie Mellon Univ.) the “Design Theory” Special Interest group of the Design Society. He has published, with Benoit Weil and Armand Hatchuel, “Strategic Management of Innovation and Design” (Cambridge University Press, 2010) and “design theory” (Springer, 2017) and several papers in international top-level journals. He is area-editor in design theory for Research in Engineering Design and editor of the European Management Review.

Kumar Selvarajoo introduced systems biology and machine learning concepts and highlight how these can be combined to advance modern biomedical and food applications research through digital twin models:

The idea of developing virtual cells or digital twin models to understand and predict living systems behaviors dates back several decades ago. This is mainly due to (i) a purely curiosity-driven need to build theories of life and, (ii) the potential for quickly and safely finding cures for complex diseases by possibly testing drugs in silico prior to actual testing on real organisms.

Systems biology, which combines the strengths of multiple disciplines (physics, chemistry, computer science, mathematics, engineering), and machine learning have been employed to interpret the recent deluge of large-scale biological data generation across multiple omics.

Kumar Selvarajoo is a Senior Principal Investigator for Computational Biology & Omics at the Bioinformatics Institute, ASTAR, and an Adjunct Associate Professor at the School of Medicine, National University of Singapore, and the School of Biological Sciences, Nanyang Technological University.

Over the past 20 years, he has lead teams in Computational Biology, Systems Biology, Bioinformatics, Statistical Genetics, Data Analytics and Machine learning.

The future of diagnostics has arrived, and it’s called PillBot!

The audience of "Science in the Age of Experience 2024 - Generative Sciences for Society" was able to discover the unlimited power of technology as it redefines healthcare and sets new standards in modern medicine.After an inspiring description of this incredible human and technological adventure, Torrey Smith, CEO of Endiatx, showed us on stage what the future of medicine would be like by swallowing the Pillbot to demonstrate its potential and the challenge taken up by its incredible teams.

Endiatx is reshaping the future of healthcare with PillBot, a groundbreaking micro-robot that autonomously navigates the human stomach, pushing the boundaries of what’s possible in medical diagnostics. Powered by cutting-edge robotics and AI, PillBot isn’t just transforming how we diagnose and monitor internal health—it’s unlocking a world of real-time, minimally invasive, and unprecedented medical insights.

Torrey Smith was on stage with Quentin Caron (Endiatx Chief Engineer), Thomas Froger Silva (Endiatx Head of Manufacturing) and Kevin Jonshon (Endiatx head of Hardware).

Jean Tirole is honorary chairman of the Foundation JJ Laffont-Toulouse School of Economics (TSE) and of the Institute for Advanced Study in Toulouse (IAST), and scientific director of TSE-Partnership and is affiliated with MIT

His research is very broad from industrial organization to regulation to finance, macroeconomics and banking, and psychology-based economics. Amazingly he has published over 200 articles and 12 scientific books.

One of the many awards he has received is none other than the Nobel Prize in Economics in 2014. We wanted to conclude Science in the Age of Experiences with Mr Tirole of course for his works on economy as a scientific domain, but also because as we underlined the Generative Economy, the business dimension is central to applied science.

In the opening remarks for the 10th International Virtual Human Twin Symposium, Steve Levine - Senior Director, Virtual Human Modeling at Dassault Systèmes and Symposium Master of Ceremonies, - reflects on a decade of groundbreaking progress, from the humble origins of the Living Heart Project to the dawn of global adoption of virtual human twins in Healthcare. He sets the stage for the 2-day symposium by emphasizing its role in fostering interdisciplinary collaboration, innovation, and a shared vision for transforming healthcare through precision medicine, encouraging participants to envision the next frontier of possibilities.

In his keynote, Bernard Charlès reflects on Dassault Systèmes' transformative journey into healthcare, emphasizing the pivotal role of the virtual human twin in revolutionizing patient care and research. He highlights the vast ecosystem fostered by the Living Heart and MediTwin projects, showcasing their impact on global innovation and interdisciplinary collaboration.

In her keynote, Claire Biot outlines the transformative potential of virtual human twins in revolutionizing healthcare by fostering therapeutics innovation and empowering individual health journeys. She emphasizes the shift toward predictive, preventive, and patient-centric care, enabled by multidisciplinary collaboration and advanced virtual twin technologies.

In his keynote, Dr. Vibert highlights the transformative potential of digital twins in oncology, cardiology, and neurology, emphasizing their integration of multi-scale biological, clinical, and environmental data. He underscores their critical role in personalizing cancer treatments, improving patient outcomes, and driving precision medicine forward through innovative collaborations like the MediTwin initiative.

An overview of the MediTwin project, showcasing how virtual twins are transforming healthcare through multiscale, multisystem modeling. It emphasizes a systems viewpoint, collaborative innovation, integrating real patient data to improve diagnosis, treatment, and prevention across key areas like cardiology, oncology, and neurology.

Discover real-world applications made possible by expert research and advancements in virtual human twin technologies.

VIRTUAL TWINS FOR CLINICAL RESEARCH & TRAINING

Sharmila Anandasabapathy, MD, VP & Sr Assoc Dean, Global Programs & Professor of Medicine in Gastroenterology

Dr. Anandasabapathy explores the groundbreaking impact of generative sciences and virtual twins in transforming global healthcare. From revolutionizing cancer prevention to predicting liver toxicity, optimizing cardiac devices, and tackling the challenges of space medicine, she showcases cutting-edge innovations driving precision medicine. With a vision of global equity and collaboration, she aspires for a future where technology and human ingenuity converge to deliver life-changing advancements in healthcare worldwide.

AUTOMATED SOFT MATTER MATERIAL MODEL DISCOVERY AND UNIVERSAL FINITE ELEMENT ANALYSIS IMPLEMENTATION

Mathias Peirlinck, Assistant Professor, Dept. Biomechanical Engineering, Delft University

Cutting-edge advancements in automated material model discovery using constitutive neural networks are transforming the simulation of soft tissues like the heart, arteries or the brain, . This groundbreaking work revolutionizes human biomechanics by using AI-driven neural networks to automate the discovery of tissue material models from billions of possibilities. By eliminating bias and simplifying integration into finite element simulations, it empowers precise, user-friendly modeling of heart and vascular tissues, driving advances in understanding disease mechanisms, personalizing treatments, and developing next-generation medical devices.

THE LIVING EYE PROJECT

​​​​​​​Joseph Rizzo, MD, Director Healthcare & Life Sciences Research, Mass Eye and Ear Institute

The Living Eye Project is pioneering the creation of the most detailed virtual twin of the human eye, enabling advanced simulations to study and treat vision challenges. By uniting engineering and biomedical expertise, this project aims to revolutionize ophthalmological treatments,

Steve Levine, Sr. Director Virtual Human Modeling, Dassault Systèmes

In reflecting on the transformative journey of the Living Heart Project, Steve Levine shares a deeply personal narrative of a decade marked by innovation, resilience, and community. He poignantly ties his own life-saving experience with virtual twin technology to the collective achievements of a global network dedicated to revolutionizing healthcare. His reflections underscore the profound impact of technology, collaboration, and shared purpose in reshaping how we approach medicine and will inspire future advancements in virtual human modeling in the coming decade.

Patrick JOHNSON  – Vice President of Research, Dassault Systèmes

​​​​​​​Patrick Johnson’s keynote explores the transformative power of virtual human twins in revolutionizing healthcare through personalized medicine and collaborative innovation. By highlighting advancements in in silico clinical trials, drug safety, and tailored medical interventions, he demonstrates how virtual twins are breaking barriers to accelerate treatments, improve outcomes, and bring groundbreaking precision to global healthcare.

David HOGANSON, Cardiac Surgeon, Director, Comp. 3D Vis Program,  Boston Children’s Hospital & Harvard Medical School  

Dr. David Hoganson’s keynote showcases how 3D modeling, virtual twins, and computational fluid dynamics are revolutionizing surgical planning for complex pediatric heart conditions. By enabling precise, patient-specific simulations, this groundbreaking approach is improving outcomes, preventing complications, and setting a new standard for personalized cardiovascular care in children.

Katie Bales, Investor, Patient Advocate and Mother

In a heartfelt and inspiring presentation, Katie tells the story of JJ—a young boy born with a complex congenital heart defect—illuminating the life-changing impact of the Living Heart Project. Through cutting-edge virtual twin technology, JJ’s surgeons at Boston Children’s Hospital achieved unparalleled precision in planning his care, transforming what was once uncertainty into confidence, hope, and remarkable recovery. This presentation underscores how innovation is not just advancing science but deeply affecting lives, paving the way for a future where such transformative care becomes accessible to every child and family.

Saila RINNE - Director, eHealth, Well-Being and Ageing - EU Commission

​​​​​​​Saila Rinne unveils the European Commission's bold vision for Virtual Human Twins, emphasizing their transformative potential in revolutionizing healthcare across Europe. With a commitment to innovation, collaboration, and equity, this initiative aims to harness digital twins to drive precision medicine, improve patient outcomes, and set a global standard for technological advancement in healthcare.

Liesbet GERIS, Executive director, VPH Institute / University of Liège

Liesbet Geris introduces the EDITH project, showcasing its pioneering work in creating a Virtual Human Twin ecosystem. By addressing ethical, technical, and collaborative challenges, EDITH aims to transform healthcare through accessible and reliable digital twin platforms, driving innovation and inclusivity in precision medicine across Europe.

Laure FOURNIER, Professor of Radiology chez Université Paris Cité

The presentation explores the TwinOnco project, focusing on enhancing oncology patient follow-up by integrating AI-powered virtual twins. It addresses challenges in tumor monitoring, standardizing lesion measurements, and evolving from statistical tumor assessments to individualized, holistic evaluations. This approach aims to improve precision in tracking treatment responses, managing tumor burden, and optimizing patient outcomes across diverse oncology cases.

The application of pseudo-healthy virtual twins for brain anomaly detection in Alzheimer’s disease, leveraging patient-specific abnormality mapping. It emphasizes advancements in early diagnosis and personalized care by integrating AI-driven imaging and predictive analytics.

• Ninon Burgos,CNRS researcher at the Paris Brain Institute
• Louise Moreau, Living Brain Technology Specialist, Dassault Systèmes
• Dr. Nicolas Villain, AP-HP & associate Professor of Neurology at Sorbonne University
• Baptiste Demurger,Health Innovation Project Manager, Dassault Systèmes

This dynamic panel delves into the regulatory and ethical challenges of integrating virtual human twins into clinical applications. Featuring experts from consulting, academia, and industry, it explores innovative solutions to ensure safe, effective, and ethically responsible adoption of this transformative technology in healthcare.

Moderator: Jean Colombel, Dassault Systèmes

Panelists:

• Emmanuel Voisin, Voisin Consulting,
• Sharmila Anadasabapathy, Baylor College of Medicine,
• Sébastien Roseet, Dassault Systèmes

This panel brings together leading voices from the FDA, clinical practice, research, and industry to explore the transformative potential of in silico clinical trials. The discussion focuses on the recently published 'Playbook,' a comprehensive guide detailing how to use virtual twins as regulatory evidence, highlighting pathways to accelerate medical innovation, improve patient safety, and redefine the future of clinical research.

​​​​​​​Panelists:

• Brent Craven, FDA; Kenneth Aycock, FDA;
• David Hoganson, Boston Children’s Hospital;
• Claudio Capelli, UCL;
• Steve Levine, Dassault Systèmes
• Moderator: Jean Colombel, Dassault Systèmes

This engaging panel explores the transformative power of interdisciplinary collaborations in medical education, highlighting how scientists, engineers, and clinicians can co-create innovative solutions for advancing virtual twins in healthcare. By fostering shared goals, mutual respect, and effective communication, the discussion inspires a vision of education as a bridge to breakthroughs in precision medicine and personalized care.

Panelists:

• Mohammed Cherkaoui, Long Island University;
• Silvia Schievano, University College London;
• Irene Vignon-Clementel, INRIA;
• Valérie Ferret, Dassault Systèmes
• Moderator: Steve Levine, Dassault Systèmes

Steve LEVINE, Symposium Master of Ceremonies, Dassault Systèmes

Closing the 10th Annual Virtual Human Twin Symposium, Steve Levine reflects on the symposium’s key takeaways a decade of groundbreaking innovation and collaboration.  It concludes with a call to action for unity towards a common goal, inspiring participants to reimagine healthcare's future.